Skip to content

VEGF in Iris Tissue in Primary Congenital Glaucoma

Estimation of Vascular Endothelial Growth Factor (VEGF) in Iris Tissue in Primary Congenital Glaucoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05484050
Enrollment
30
Registered
2022-08-02
Start date
2022-09-30
Completion date
2023-06-30
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iris

Brief summary

Estimation of vascular endothelial growth factor (VEGF) in iris tissue specimen in primary congenital glaucoma through Immunohistochemistry.

Detailed description

Combined trabeculotomy with mitomycin C will done in infants with primary congenital glaucoma with histopathological examination of the the peripheral iris tissue specimen and vascular endothelial growth factor (VEGF) estimation in iris tissue specimen through Immunohistochemistry. Estimation of vascular endothelial growth factor (VEGF) in iris tissue specimen taking from ocular trauma or congenital cataract used as control.

Interventions

Estimation of VEGF through Immunohistochemistry

Sponsors

Hassan Lotfy Fahmy
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 1 Years
Healthy volunteers
No

Inclusion criteria

* primary congenital glaucoma

Exclusion criteria

* Infants with history of previous surgery. * Secondary glaucoma. * Glaucoma associated with other congenital anomalies.

Design outcomes

Primary

MeasureTime frameDescription
VEGF6 monthEstimation of VEGF grade in iris tissue through Immunohistochemistry, The grades is arranged from 0 to 5, with 0 being the lowest level and 5 being the highest level

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026